Developer docs
API playgroundTry for free, no card

Search company profiles

BMS Korea

Full company profile

uuid003hbty

Namestring
BMS Korea
Legal namestring
Bristol-Myers Squibb Company
Websiteurl
bms.com
Company typeenum
Public
Founded yearint
1989
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBrisbane, United States
HQ citystring
Brisbane
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical medicines, cell therapy products, oncology therapeutics, protein degradation research, cardiovascular treatments
Industry4 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

BMS generates revenue through the sale of prescription pharmaceutical medicines. Products are distributed through pharmacies, hospitals, and specialty treatment centers. Revenue comes from both newly launched medicines and established brands across oncology, hematology, immunology, neuroscience, and cardiovascular therapeutic areas.

bms.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Infrastructure, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BMS Korea operates as the Korean subsidiary of Bristol Myers Squibb, developing and commercializing prescription pharmaceutical medicines across five core therapeutic areas: Oncology, Hematology, Neuroscience, Immunology, and Cardiovascular. The company manufactures and sells a portfolio of approved medicines, autologous CAR T cell therapies, and supports a pipeline of 50+ investigational compounds targeting 40+ disease areas.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ~14 million patients reached globally with BMS medicines in 2025
+2 more records
Product overview1 text field

BMS Korea (Bristol Myers Squibb Korea) is the Korean subsidiary of a global biopharmaceutical company offering a portfolio of approved prescription medicines across five core therapeutic areas: Oncology, Hematology, Neuroscience, Immunology, and Cardiovascular. The company's product portfolio includes its BMS Medicines Portfolio of approved drugs, CAR T Cell Therapy (with 2 approved therapies and 3+ in clinical trials), and a robust pipeline of 50+ compounds targeting 40+ disease areas. Services include Cancer Care Patient Resources, Disease State Resources (fact sheets for various cancers), Investigational Medicine Access Programs (Pre-Approval Access and Post Study Drug Access), and Competitive Research Grants for independent investigators. Research platforms focus on protein degradation using cryo-EM technology and a comprehensive cancer research approach combining tumor intrinsic and extrinsic mechanisms across multiple therapeutic modalities including immunotherapies, protein degraders, cell therapies, targeted therapies, and antibody-drug conjugates.

Product and service1 record
1BMS Medicines Portfolio
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

BMS entered into a strategic Immuno-Oncology collaboration with Nektar Therapeutics for the development of a selective IL-2 receptor agonist. This partnership focuses on harnessing the ability to selectively target IL-2 receptors on T cells to increase immune cells in the tumor microenvironment, potentially expanding benefits to more cancer patients when combined with other mechanisms such as PD-1 inhibitors.

2Ono Pharmaceutical Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BMS collaborates with Ono Pharmaceuticals for research and development activities in Japan, Korea, and Taiwan. This partnership enables BMS to expand its presence and conduct clinical research across these Asian markets through Ono's established regional infrastructure and expertise.

bms.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BMS works with clinical trial investigators and research institutions globally to conduct clinical trials across its pipeline. The company accepts investigator-sponsored research (ISR) proposals in oncology, hematology, cardiovascular, and immunology through its FastTrack Investigator Portal.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in CAR T cell therapy (Kymriah), oncology, hematology, and cardiovascular. Highly comparable modality strategy spanning cell therapy, radioligand therapy, and small molecules.

TypeDirect peer
Description

Specialty biopharma with deep immunology (Humira/Skyrizi/Rinvoq) and oncology franchises (hematology). Comparable specialty pharma model and post-LoE pipeline replenishment challenge.

TypeDirect peer
Description

Competitor in immunology, oncology, and rare disease with a similar mix of specialty pharmaceuticals and biologics. Overlapping therapeutic area focus and global commercial model.

TypeDirect peer
Description

Competitor in oncology (checkpoint inhibitors, ADCs), cardiovascular, and respiratory/immunology. Strong direct overlap in immuno-oncology and combination therapy development.

TypeDirect peer
Description

Global biopharmaceutical leader with deep oncology (Keytruda checkpoint inhibitor) and vaccines franchises. Directly comparable to BMS across immuno-oncology, hematology, and pipeline-modality strategy.

TypeDirect peer
Description

Large-cap diversified biopharmaceutical company with overlapping oncology, immunology, and cardiovascular portfolios. Competes head-to-head across therapeutic areas and pipeline modalities.

TypeDirect peer
Description

Global biopharma with strong oncology, hematology, and immunology franchises and significant biologics manufacturing capability. Closely comparable to BMS in cancer pipeline depth and specialty pharma mix.

TypeDirect peer
Description

Global biopharma competing across oncology, immunology, and cardiovascular. Comparable in oncology pipeline build-out and specialty pharma positioning.

TypeDirect peer
Description

Direct peer across oncology, immunology, and neuroscience, with growing cardiometabolic presence. Comparable in R&D scale and global launch capability.

TypeDirect peer
Description

Diversified biopharma with overlapping oncology, immunology, and cardiovascular franchises. Comparable in scale, pipeline breadth, and global commercial reach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BMS Korea

Biopharmaceuticalsbms.com

BMS Korea firmographics

Firmographics
Name
BMS Korea
Legal name
Bristol-Myers Squibb Company
Website
https://bms.com
Company type
Public
Founded year
1989
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

BMS Korea industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Biopharmaceutical medicines
  • Cell therapy products
  • Oncology therapeutics
  • Protein degradation research
  • Cardiovascular treatments

Where BMS Korea is headquartered

Location

Headquarters

HQ city
Brisbane
HQ country
United States
HQ region
North America

Offices7 records

Markets served

BMS Korea business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. Pharmaceutical Product Sales: BMS generates revenue through the sale of prescription pharmaceutical medicines. Products are distributed through pharmacies, hospitals, and specialty treatment centers. Revenue comes from both newly launched medicines and established brands across oncology, hematology, immunology, neuroscience, and cardiovascular therapeutic areas.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

BMS Korea product offering

Product offering

Core offering

BMS Korea operates as the Korean subsidiary of Bristol Myers Squibb, developing and commercializing prescription pharmaceutical medicines across five core therapeutic areas: Oncology, Hematology, Neuroscience, Immunology, and Cardiovascular. The company manufactures and sells a portfolio of approved medicines, autologous CAR T cell therapies, and supports a pipeline of 50+ investigational compounds targeting 40+ disease areas.

Product overview

BMS Korea (Bristol Myers Squibb Korea) is the Korean subsidiary of a global biopharmaceutical company offering a portfolio of approved prescription medicines across five core therapeutic areas: Oncology, Hematology, Neuroscience, Immunology, and Cardiovascular. The company's product portfolio includes its BMS Medicines Portfolio of approved drugs, CAR T Cell Therapy (with 2 approved therapies and 3+ in clinical trials), and a robust pipeline of 50+ compounds targeting 40+ disease areas. Services include Cancer Care Patient Resources, Disease State Resources (fact sheets for various cancers), Investigational Medicine Access Programs (Pre-Approval Access and Post Study Drug Access), and Competitive Research Grants for independent investigators. Research platforms focus on protein degradation using cryo-EM technology and a comprehensive cancer research approach combining tumor intrinsic and extrinsic mechanisms across multiple therapeutic modalities including immunotherapies, protein degraders, cell therapies, targeted therapies, and antibody-drug conjugates.

Differentiator

Problem solved

Functional benefit

Products and services

  • BMS Medicines Portfolio

Quantifiable outcome

  • ~14 million patients reached globally with BMS medicines in 2025
  • +2 more outcomes

Companies that use BMS Korea

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

BMS Korea technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

BMS Korea partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Nektar TherapeuticscoreStrategic or Co-development Partner · 1 January 2018BMS entered into a strategic Immuno-Oncology collaboration with Nektar Therapeutics for the development of a selective IL-2 receptor agonist. This partnership focuses on harnessing the ability to selectively target IL-2 receptors on T cells to increase immune cells in the tumor microenvironment, potentially expanding benefits to more cancer patients when combined with other mechanisms such as PD-1 inhibitors.
  • Ono Pharmaceutical Co., Ltd.coreStrategic or Co-development PartnerBMS collaborates with Ono Pharmaceuticals for research and development activities in Japan, Korea, and Taiwan. This partnership enables BMS to expand its presence and conduct clinical research across these Asian markets through Ono's established regional infrastructure and expertise.
  • Clinical Trial InvestigatorscoreStrategic or Co-development PartnerBMS works with clinical trial investigators and research institutions globally to conduct clinical trials across its pipeline. The company accepts investigator-sponsored research (ISR) proposals in oncology, hematology, cardiovascular, and immunology through its FastTrack Investigator Portal.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

BMS Korea competitors and assessment

Company assessment

Direct peers

  • Novartis: Direct competitor in CAR T cell therapy (Kymriah), oncology, hematology, and cardiovascular. Highly comparable modality strategy spanning cell therapy, radioligand therapy, and small molecules.
  • AbbVie: Specialty biopharma with deep immunology (Humira/Skyrizi/Rinvoq) and oncology franchises (hematology). Comparable specialty pharma model and post-LoE pipeline replenishment challenge.
  • Sanofi: Competitor in immunology, oncology, and rare disease with a similar mix of specialty pharmaceuticals and biologics. Overlapping therapeutic area focus and global commercial model.
  • AstraZeneca: Competitor in oncology (checkpoint inhibitors, ADCs), cardiovascular, and respiratory/immunology. Strong direct overlap in immuno-oncology and combination therapy development.
  • Merck & Co. Global biopharmaceutical leader with deep oncology (Keytruda checkpoint inhibitor) and vaccines franchises. Directly comparable to BMS across immuno-oncology, hematology, and pipeline-modality strategy.
  • Pfizer: Large-cap diversified biopharmaceutical company with overlapping oncology, immunology, and cardiovascular portfolios. Competes head-to-head across therapeutic areas and pipeline modalities.
  • Roche: Global biopharma with strong oncology, hematology, and immunology franchises and significant biologics manufacturing capability. Closely comparable to BMS in cancer pipeline depth and specialty pharma mix.
  • GSK: Global biopharma competing across oncology, immunology, and cardiovascular. Comparable in oncology pipeline build-out and specialty pharma positioning.
  • Eli Lilly: Direct peer across oncology, immunology, and neuroscience, with growing cardiometabolic presence. Comparable in R&D scale and global launch capability.
  • Johnson & Johnson: Diversified biopharma with overlapping oncology, immunology, and cardiovascular franchises. Comparable in scale, pipeline breadth, and global commercial reach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

BMS Korea social profiles

Digital presence

BMS Korea financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BMS Korea leadership team

Management profile

Number of profiles

BMS Korea subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

BMS Korea funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BMS Korea M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BMS Korea

What does BMS Korea do?

BMS Korea operates as the Korean subsidiary of Bristol Myers Squibb, developing and commercializing prescription pharmaceutical medicines across five core therapeutic areas: Oncology, Hematology, Neuroscience, Immunology, and Cardiovascular. The company manufactures and sells a portfolio of approved medicines, autologous CAR T cell therapies, and supports a pipeline of 50+ investigational compounds targeting 40+ disease areas.

Is BMS Korea a public or private company?

BMS Korea is a public company. It is classified as public and is currently operating.

When was BMS Korea founded?

BMS Korea was founded in 1989. It employs 101 to 250 people.

Where is BMS Korea based?

BMS Korea is headquartered in Brisbane, United States, in the North America region.

How does BMS Korea make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are BMS Korea's main competitors?

Direct peers on record are Novartis, AbbVie, Sanofi, AstraZeneca, Merck & Co., Pfizer, Roche, GSK, Eli Lilly and Johnson & Johnson.

Does BMS Korea have an API?

No public API is recorded for BMS Korea.

What industry is BMS Korea in?

BMS Korea's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NateBMS, 신약 성장에 2026년 매출 전망 상향…인수 관련 비용에 EPS 전망은 하향 : 네이트 뉴스Bristol Myers Squibb raised its 2026 annual revenue forecast to $497.5–502.5 billion, citing strong new drug sales, but lowered its adjusted EPS forecast to $6.35–6.55 due to acquisition and licensing costs. The company reported Q3 revenue of $13.1 billion, beating estimates, and plans to restart a CAR-T trial in early 2027.NaverBMS 중단 이후 돌파구는…이승주 오름 대표 “새 페이로드서 성과 내겠다”Orem Therapeutics will continue its own clinical trials of ORM-1153 and develop new payload platforms after BMS halted its blood cancer candidate. The company plans to test GSPT1 proteasome inhibitors and expand into solid tumors and autoimmune diseases, with a Phase 1 trial of about 42 patients expected to yield initial data by late 2027.NateBMS 중단 이후 돌파구는…이승주 오름 대표 "새 페이로드서 성과 내겠다" : 네이트 뉴스Lee Seung-ju, CEO of Orem Therapeutics, said the company is researching a new payload platform for its DAC drugs, aiming to expand beyond GSPT1. The company has about 250 billion won in cash and plans to continue ORM-1153's Phase 1 trial, with initial data expected by late 2027.NaverMSD·BMS, 키트루다·옵디보 특허만료 앞두고 대응 다각화MSD and BMS face patent expirations for Kite and Opdivo in 2028, prompting diversification. Kite and Opdivo each contributed half and a quarter of their respective firms' second-quarter revenue, respectively. Both companies are pursuing subcutaneous formulations and new growth assets to offset the loss.Endpoints NewsRoche takes victory lap with lung cancer pill's win over Amgen, BMSRoche's next-gen KRAS G12C inhibitor cut the risk of death by 44% in previously treated mutant non-small cell lung cancer in a head-to-head trial. The company took a victory lap at ESMO, citing the win over Amgen and BMS.Ars TechnicaPharmaceutical companies are the world’s most ethicalCovalence ranked pharmaceutical companies Merck, GSK, and BMS among the top ten most ethical, using 45 criteria including labor standards and human rights. The ranking surprised the author, who noted pharmaceutical companies are typically criticized for drug costs and patent enforcement.